Relay Therapeutics, Inc. (RLAY) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Relay Therapeutics, Inc. on February 3, 2026. The filing discloses a significant regulatory milestone regarding the Company's clinical development program.
Key Financial Metrics
This filing is a regulatory disclosure and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Events
- Regulatory Designation: The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to zovegalisib (RLY-2608).
- Indication: The designation applies to zovegalisib in combination with fulvestrant for the treatment of adults with PIK3CA mutant hormone receptor positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) locally advanced or metastatic breast cancer.
- Patient Population: The treatment is indicated for patients following recurrence or progression on or after treatment with a CDK4/6 inhibitor.
Outlook, Risks, and Management Commentary
The filing references a press release (Exhibit 99.1) detailing the announcement. The Breakthrough Therapy designation is intended to facilitate the development and expedite the review of drugs to treat serious conditions. The filing explicitly states that the information is furnished and not "filed" for purposes of Section 18 of the Exchange Act, limiting liability and incorporation by reference.
Investor Verification Checklist
- Verify the specific clinical trial data supporting the Breakthrough Therapy designation in the attached press release (Exhibit 99.1).
- Confirm the current development timeline and expected next steps for zovegalisib following this designation.
- Review the Company's most recent 10-Q or 10-K for updated cash runway and burn rate, as this 8-K contains no financial data.
- Assess the competitive landscape for PIK3CA mutant HR+/HER2- breast cancer treatments.